Clinical Trials Logo
  1. Home
  2. Neovascular Glaucoma
  3. NCT00441181
  4. Details
NCT00441181 Clinical Trial

Effects of Travoprost on Neovascular Glaucoma

Neovascular Glaucoma Clinical Trial

Official title:
Effects of Travoprost on Neovascular Glaucoma

Clinical Trial Details — Status: Withdrawn

Administrative data
NCT number NCT00441181
Other study ID # UNIFESP 2007-02
Secondary ID
Status Withdrawn
Phase N/A
First received February 27, 2007
Last updated June 21, 2011
Start date January 2008
Est. completion date December 2008

Study information
Verified date February 2007
Source Federal University of São Paulo
Contact n/a
Is FDA regulated No
Health authority Brazil: National Health Surveillance Agency
Study type Interventional

Clinical Trial Summary

Prostaglandin analogues have not been used in the treatment of neovascular glaucoma because of suspicious lack of efficacy. This study aims at assessing the effect of travoprost on neovascular glaucoma.

Recruitment information / eligibility
Status Withdrawn
Enrollment 40
Est. completion date December 2008
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Neovascular glaucoma of known cause

- Older than 18 years

- Previously submitted to retinal photocoagulation

- Under medical treatment to glaucoma

Exclusion Criteria:

- Need of antiglaucomatous surgery

- Previous ocular surgery in the last 6 months

- Pregnancy

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

Intervention

Drug:
• Travoprost

Locations
Country Name City State
Brazil Federal University of São Paulo São Paulo

Sponsors (1)
Lead Sponsor Collaborator
Federal University of São Paulo

Country where clinical trial is conducted

Brazil, 

Outcome
Type Measure Description Time frame Safety issue
Primary Intraocular pressure
Secondary Inflammation
See also
  Status Clinical Trial Phase
Active, not recruiting NCT00491712 - Comparison of Efficacy Between Silicone Ahmed Glaucoma Valves With and Without Intravitreal Triamcinolone Injection N/A
Recruiting NCT04519619 - Study to Learn More About Safety of Aflibercept Injection in Japanese Patients With Neovascular Glaucoma (NVG)
Completed NCT01370135 - Study to Evaluate the Effects of Ranibizumab (Lucentis) for Patients With Rubeosis and Neovascular Glaucoma N/A
Completed NCT04970251 - Aflibercept as Adjunctive Treatment for Filtration Surgery in Neovascular Glaucoma N/A
Completed NCT02805257 - Ahmed Glaucoma Valve Surgery With Mitomycin-C Phase 2
Recruiting NCT02067013 - Analysis of Aqueous and Vitreous Humor Phase 2
Completed NCT00524758 - Oculusgen (Ologen) Glaucoma MMC Control in Estonia Phase 3
Withdrawn NCT00727038 - Lucentis for New Onset Neovascular Glaucoma Phase 1/Phase 2
Not yet recruiting NCT02947867 - Trial of Aganirsen in iCRVO Patients at Risk of Developing NVG Phase 2/Phase 3
Completed NCT01711879 - Use of Intravitreal Aflibercept Injection for Neovascular Glaucoma N/A
Terminated NCT02260219 - Comparative Study, Safety and Efficacy, Ahmed Glaucoma Drainage Device, Model M4 Model S2 in Neovascular Glaucoma N/A
Completed NCT01051583 - Avastin as an Adjunct to Diode Laser in the Treatment of Neovascular Glaucoma Phase 2
Completed NCT05156021 - A Study on the Treatment Strategy of NVG Secondary to PDR N/A
Terminated NCT01301378 - Patch Graft Material Safety and Effectiveness in Covering Glaucoma Drainage Device Tube N/A
Not yet recruiting NCT05316142 - Any Unique Identifier Assigned to the Protocol by the Sponsor N/A
Recruiting NCT04844619 - KDR2-2 Suspension Eyedrop in the Treatment of Neovascular Glaucoma (KDR-NVG) Trial Phase 1
Completed NCT03154892 - The Effect of Conbercept Injection Through Different Routes for Neovascular Glaucoma N/A